Do Aminopenicillins Have a Role in Treating Ampicillin-Resistant Enterococcus UTIs?
Abstract
Urinary tract infections caused by Enterococcus species are a frequent clinical challenge. The rising prevalence of ampicillin resistance often seemingly precludes the use of aminopenicillins. However, evidence suggests that aminopenicillins may retain clinical efficacy, even when susceptibility testing indicates resistance. Integrating available pharmacokinetics/pharmacodynamics and clinical data and risk-benefit considerations, we seek to address the question: Can aminopenicillins still be a viable treatment option in the management of ampicillin-resistant Enterococcus infections?
Read the paper
Related studies
- Pharmacokinetic aspects of retinal drug delivery
- A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis
- From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics
- Capsaicin, a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion of Staphylococcus aureus
- In Vitro Pharmacodynamic Evaluation of the Mutant Selection Window Hypothesis Using Four Fluoroquinolones against Staphylococcus aureus
- Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational Modeling
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.